Skip to content

Company · founded 1999

NeuroPace (United States)

Mountain View, United States · neuropace.com

Manage this page

Citations, last 5 years: 581
Works, last 5 years: 36
h-index: 73
Scientists listed: 8
Grants since 2016: 7

Grants received

2021–2026 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$30.4kEpilepsy research and treatment

2021–2026 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$3MEpilepsy research and treatment

2021–2026 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$2.6MEpilepsy research and treatment

2021–2026 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$1.7MEpilepsy research and treatment

2021–2026 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$831.4kEpilepsy research and treatment

2021–2027 · cooperative agreement · UH3

Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Martha J Morrell · NeuroPace (United States) · funded by National Institutes of Health

$1.6M

2019 · research · R44

Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage

Robert Zaczek · NeuroPace (United States) · funded by National Institutes of Health

$125k